key: cord-0978450-xvhg4m16 authors: Ye, Qing; Wang, Bili; Mao, Jianhua; Fu, Junfen; Shang, Shiqiang; Shu, Qiang; Zhang, Ting title: Epidemiological analysis of COVID‐19 and practical experience from China date: 2020-04-10 journal: J Med Virol DOI: 10.1002/jmv.25813 sha: aaf64a3afb12a2be37ba7e6cd242f755f8e17058 doc_id: 978450 cord_uid: xvhg4m16 The rapid spread of the epidemic has aroused widespread concern in the international community. Severe acute respiratory syndrome coronavirus 2 (SARS‐COV‐2) originated from Wuhan's Huanan wholesale seafood market, with bats as the likely original hosts and pangolins as potential intermediate hosts. The current source of the disease is mainly patients infected with SARS‐COV‐2. Patients in the incubation period may also become sources of infection. The virus is mainly transmitted via respiratory droplets and contact, and the population is generally susceptible. The epidemic has progressed through the local outbreak stage and community transmission stage due to exposure at Wuhan's Huanan wholesale seafood market and is now in the stage of large‐scale transmission due to the spread of the epidemic. The basic productive number (R0) at the beginning of the epidemic was 2.2, with an average incubation period of 5.2 days. The proportion of critically ill patients was 23.4%, the mortality rate was lower than those of SARS and Middle East respiratory syndrome, and 96.5% of deaths occurred in Hubei Province, where the outbreak occurred first. Among them, elderly men with underlying diseases had a higher mortality rate. Chinese medical staff have summarized a set of effective strategies and methods in the diagnosis and treatment of this disease that are worthy of reference for their international counterparts. With powerful government intervention and the efforts of Chinese medical staff, China's outbreak has gradually improved. SARS-CoV-2 is the seventh type of coronavirus isolated in humans. This coronavirus belongs to the genus β and has an envelope; its particles are round or oval, often polymorphic, and 60 to 140 nm in diameter. The genetic characteristics of SARS-CoV-2 are significantly different from those of SARS-CoV and MERS-CoV. Current research shows that SARS-CoV-2 has more than 85% homology with bat SARS-like coronavirus (Bat-SL-CoV ZC45). 2 Therefore, it is now believed that the original host of SARS-CoV-2 may have been Rhinolophus sinicus. 3 8 Post hoc investigations also revealed that there was a wildlife trade in this market, and SARS-CoV-2 has also been isolated from the market's environment. Human-to-human transmission emerged shortly thereafter. 9 Patients with COVID-19 have become the main source of infection. COVID-19 may be capable of transmission during the incubation period. 10, 11 These patients are difficult to diagnose and isolate in time, which causes great difficulties in the prevention and control of the disease. However, up to date, there is no enough evidence to support the role of asymptomatic patients in the transmission of COVID-19. In addition, the presence of the virus can be detected in patients during the recovery stage, especially in fecal specimens requiring longer detoxification times, indicating the possible risk of fecal-oral transmission. 11 SARS-CoV-2 is a positive-stranded RNA virus that is susceptible to gene mutation and recombination, but so far, no significant mutations have been found in humans or the environment. 2, 12 3 | METHOD OF SPREAD At present, droplets inhaled into the respiratory tract and contact transmission are considered to be the most important routes of transmission. There is no direct evidence showing that COVID-19 can be transmitted through aerosols. The WHO believes that further evidence is needed to assess the possibility of aerosol transmission. However, some of the observations suggest that aerosol propagation is possible under the condition of long exposure to high concentrations of aerosols in a relatively closed environment. In the early stages of the outbreak of SARS-CoV-2 pneumonia, it is uncertain whether stool samples from patients are infectious. However, Lu et al, 2 using a computer structural simulation, found that the S-protein of SARS-CoV-2 can bind to human angiotensin-converting enzyme 2 (ACE2) in the spatial conformation. After that, Letko et al 13 synthesized the S-protein of SARS and the receptor-binding domain (RBD) of SARS-CoV-2 in vitro and reacted with known human coronavirus receptors, respectively. As a result, the RBD of SARS-CoV-2 is similar to the S protein in SARS, and it can directly bind to human ACE2. ACE2 is a metalloproteinase belonging to a type I transmembrane glycoprotein, and it can be expressed in the small intestine. 14, 15 In our laboratory, it was also found that nucleic acid amplification testing of stool samples can still be positive for a long time after oral swab samples become negative. In addition, a large number of clinical studies have shown that a certain proportion of SARS-CoV-2 pneumonia patients develop symptoms of diarrhea. 10, 16 It can be concluded that during the development of the disease, there is a greater possibility of the virus in the stool. Recently, SARS-CoV-2 has been isolated from the stool of confirmed patients in Wuhan and Shenzhen, China, and in the United States, 17 indicating that the virus can replicate and survive in the digestive tract. However, it is not clear whether the infection and transmission are caused by eating food contaminated with the virus. Through the analysis of the current epidemic situation, some scholars believe that viruses in feces may be retransmitted by the aerosol formation of virus-containing droplets. SARS-CoV-2 also has adverse effects on fetuses and infants, including restricted intrauterine growth, premature birth, spontaneous abortion, and perinatal death. 18 However, the possibility of intrauterine mother-to-child transmission of COVID-19 is very low, and neither of the two existing retrospective clinical studies have found direct evidence of intrauterine vertical transmission. 19, 20 Those in close contact with patients with SARS-CoV-2 pneumonia, including the family members of patients, are at high risk for developing the SARS-CoV-2 infection. Medical staff who treat patients also have a high risk of infection. Nine percent of the patients admitted to Zhongnan Hospital of Wuhan University from 1 to 28 January 2020, were the medical staff. 22 By the end of 29 January 2020, survey data from 552 hospitals in 31 provinces in China showed that the infection rate of medical staff was as high as 2.09%. 16 According to a WHO report, as of 23 March 2020, the world has According to the available data, the mortality rate of COVID-19 in China is lower than those of SARS (10%) 23 and MERS (40%). 24 By 23 March 2020, 96.5% (3160/3276) of the deaths caused by SARS-CoV-2 pneumonia in China was in Hubei Province, and the earlier the onset of disease was, the higher the mortality rate, suggesting that the pathogenicity may gradually decrease as the virus spreads, which may also occur because of the improving ability of medical staff to diagnose and treat the disease. The National Health Commission of China notified on 4 February 2020, that the population is generally susceptible to the virus, and more than 80% of the deaths are elderly people over 60 years old; at the same time, more than 75% of the deaths have underlying diseases. Overall, men are linked to a higher risk of death. The specific data in this section are shown in Table 1 others were all in mild condition. Among the seven cases reported in the existing literature outside China, except for one case where the patient died, the remaining cases were in stable condition (Table 3) . According to the latest data as of 23 March 2020, more than found that about 0.1% of patients will be tested positive for nucleic acid again after discharge. 50 There are many reasons for the positive nucleic acid test of discharged patients. 51 The reagent itself, detection method, sampling method, and so on will affect the positive rate. In addition, the possibility of disease recurrence cannot be ruled out too. Genomic analysis of the virus from different regions, different periods and different sources of patients revealed that SARS-CoV-2 was stable and showed no major variation. So once the patient is cured with immunity against the virus, there is little chance of reinfection. The detection of SARS-CoV-2 specific IgM and IgG antibodies is an effective means to determine whether a patient has immunity against SARS-CoV-2. But these patients still have the potential to infect others. Therefore, after the patient is discharged from the hospital, it is recommended to continue the isolation management and health condition monitoring for 14 days. Here are some tips and considerations for self-isolation: wear a mask, live in a single room with good ventilation, reduce close contact with family members, separate meals, good hand hygiene, and avoid outdoor activities. It is also recommended to visit the hospital for reexamination on the 14th and 28th days after discharge. In the early stages of the epidemic, the Chinese government adopted the principles of "four early" and "four centralization" to address the epidemic so that the epidemic situation was effectively controlled. The so-called "four early" principle is early detection, early reporting, early isolation, and early treatment. Early detection and isolation of SARS-CoV-2-infected people, moving the prevention and control barrier forward, accelerating the grid-based management of the community, improving detection capabilities, optimizing the diagnosis and treatment process, and shortening the diagnosis time can effectively block the spread of the epidemic and reduce the infection rate. The principle of "four centralization" is to centralize patients, centralize experts, centralize resources, and centralize treatment. Patients with severe illness are centralized at the best hospital with the strongest comprehensive capacity for treatment. At the same time, to centralize resources and experts to treat critically ill patients, multidisciplinary and comprehensive individualized diagnosis and treatment are applied in accordance with "one person, one strategy," and finally, the mortality rate is effectively reduced. In addition, more than 37 000 medical staff from other parts of China participated in the treatment of patients with SARS-CoV-2 pneumonia in Wuhan, Hubei, which fully reflects the noble qualities and good professionalism of Chinese medical staff. It has not been long since the occurrence of SARS-CoV-2 pneumonia, there are relatively few reports in the literature, and some opinions need to be further verified by multicenter big data. In addition, infectious diseases have different characteristics at different stages. Whether some of the findings and opinions have always been applicable needs further evaluation. The SARS-CoV-2 originated from the Huanan seafood market in China has now been controlled and has gradually improved. This study was supported by the Zhejiang University special scientific research fund for COVID-19 prevention and control. The authors declare that there are no conflict of interests. Dr. SS and QS had full access to all of the data in the study and takes A novel coronavirus from patients with pneumonia in China Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Novel coronavirus takes flight from bats? A new coronavirus associated with human respiratory disease in China Coronavirus infections-more than just the common cold Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study China coronavirus: what do we know so far? Clinical features of patients infected with 2019 novel coronavirus in Wuhan Initial cluster of novel coronavirus (2019-nCoV) infections in Wuhan, China is consistent with substantial human-to-human transmission A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Transmission of 2019-nCoV infection from an asymptomatic contact in Germany A pneumonia outbreak associated with a new coronavirus of probable bat origin Functional assessment of cell entry and receptor usage for lineage B-coronaviruses, including 2019-nCoV ACE2-from the renin-angiotensin system to gut microbiota and malnutrition Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus Clinical characteristics of 2019 novel coronavirus infection in China First case of 2019 novel coronavirus in the United States Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China WHO warns that death rate from SARS could reach 10% Middle East respiratory syndrome Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage Clinical features and high resolution CT imaging findings of preliminary diagnosis novel coronavirus pneumonia Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in china Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia A novel coronavirus outbreak of global health concern Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study novel coronavirus and infectious pneumonia China's first child severe new coronavirus pneumonia The reportes of two cases of new coronavirus infection in children A case of novel coronavirus infection in a 3-month-old infant First case of 2019 novel coronavirus infection in children in Shanghai Novel coronavirus infection in hospitalized infants under 1 year of age in China First imported case of 2019 novel coronavirus in Canada, presenting as mild pneumonia Importation and human-tohuman transmission of a novel coronavirus in Vietnam Journey of a Thai taxi driver and novel coronavirus Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia The first 2019 novel coronavirus case in Nepal Interpretation of "Guidelines for the diagnosis and treatment of novel coronavirus (2019-nCoV) infection by the National Health Commission (trial version 5 Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial Recurrence of positive SARS-CoV-2 RNA in COVID-19: a case report Cause analysis and treatment strategies of "recurrence" with novel coronavirus pneumonia (COVID-19) patients after discharge from hospital